Report: Lilly must buy company or be acquired

Eli Lilly is set to lose the most revenue from its pharmaceuticals as a result of the patent cliff. Indeed, the drugmaker will say goodbye to more than 50 percent of its sales through 2020 as its brand name drugs lose their market exclusivity, according to estimates by Bernstein Research analyst Tim Anderson. And, as BNET's Jim Edwards notes this morning, the numbers suggest that Lilly must either acquire another company or be acquired. Story